Skip to main content
LEAP THERAPEUTICS, INC. logo

LEAP THERAPEUTICS, INC. — Investor Relations & Filings

Ticker · LPTX ISIN · US52187K2006 LEI · 549300T31SMMJ2DDLI13 US Manufacturing
Open in API
Filings indexed 584 across all filing types
Latest filing 2021-05-29 Director's Dealing
Country US United States of America
Listing US LPTX

About LEAP THERAPEUTICS, INC.

https://www.leaptx.com/

Leap Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted and immuno-oncology therapeutics for cancer. Its most advanced clinical candidate, DKN-01 (sirexatamab), is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein, being developed for patients with esophagogastric, gynecologic, and colorectal cancers. The company's pipeline also includes FL-301, a monoclonal antibody targeting Claudin18.2 for gastric and pancreatic cancer, and FL-501, a preclinical antibody targeting the growth and differentiation factor 15 (GDF-15) protein.

Recent filings

Filing Released Lang Actions
OWNERSHIP DOCUMENT
Director's Dealing
2021-05-29 English
OWNERSHIP DOCUMENT
Director's Dealing
2021-05-29 English
FORM 8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated May 14, 2021, by Leap Therapeutics, Inc. It announces the company's financial results for the quarter ended March 31, 2021, and includes a press release as an exhibit. The text explicitly states that the full financial results are in the press release attached as Exhibit 99.1, and the 8-K itself is a current report announcing these results. The document is 4330 characters long, which is relatively short and consistent with an earnings release announcement rather than a full financial report. According to the rules, initial announcements of quarterly financial results with key highlights only are classified as Earnings Release (ER). Therefore, this document is best classified as an Earnings Release (ER).
2021-05-14 English
FORM 10-Q
Interim / Quarterly Report Q1 2021
2021-05-14 English
DEFA14A
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a Schedule 14A filing, which is a definitive proxy statement and additional materials related to the Annual Meeting of Stockholders. It includes details about the meeting date, proposals to be voted on, voting instructions, and how to access the proxy materials. It does not contain the actual annual report or financial statements but rather serves as solicitation material for shareholder voting. This matches the description of Proxy Solicitation & Information Statement filings.
2021-04-28 English
DEF 14A
Proxy Solicitation & Information Statement
2021-04-28 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.